1998
DOI: 10.4269/ajtmh.1998.58.225
|View full text |Cite
|
Sign up to set email alerts
|

Variant- and strain-specific immunity in Saimiri infected with Plasmodium falciparum.

Abstract: Abstract. Variant-and strain-specific immunity to malaria in Saimiri monkeys infected with homologous O and R variants of the Palo Alto strain (FUPSP) of Plasmodium falciparum or by various heterologous divergent strains were studied. Following homologous reinfections, the primary immune response in monkeys was effective only against the same variant type but not against the other variant, which differed only by antigens exposed at the surface of the infected red blood cell. In contrast, after two successive i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
6
0

Year Published

1999
1999
2012
2012

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 22 publications
(34 reference statements)
1
6
0
Order By: Relevance
“…This is consistent with the observation that MSP4/5 sequences from strains of P. yoelii, recently shown to be conserved within P. yoelii, induced cross-protection against heterologous P. yoelii challenge: however, less cross-protection was observed with MSP4/5 from P. berghei against P. yoelii challenge (20). Cross-protection following exposure to P. falciparum strains is also described (7,17,26). We suggest that a multiepitope or polyprotein-based cross-protective blood-stage vaccine could feasibly be engineered for delivery in a DNA prime-virus boost approach as described for liver stage vaccines (38,45).…”
Section: Discussionsupporting
confidence: 78%
“…This is consistent with the observation that MSP4/5 sequences from strains of P. yoelii, recently shown to be conserved within P. yoelii, induced cross-protection against heterologous P. yoelii challenge: however, less cross-protection was observed with MSP4/5 from P. berghei against P. yoelii challenge (20). Cross-protection following exposure to P. falciparum strains is also described (7,17,26). We suggest that a multiepitope or polyprotein-based cross-protective blood-stage vaccine could feasibly be engineered for delivery in a DNA prime-virus boost approach as described for liver stage vaccines (38,45).…”
Section: Discussionsupporting
confidence: 78%
“…Thus, an experimental P. falciparum infection can boost vaccine-induced antibody responses. It is In the present study, we did not perform a second challenge to examine the effect of a natural boost on protection because Saimiri monkeys become largely resistant to homologous challenge after one infection (6).…”
Section: Discussionmentioning
confidence: 99%
“…Immunity to malaria is commonly species, stage, strain, and variant specific (22)(23)(24). Thus, an ideal malaria vaccine should comprise multiple epitopes that would cover various stages of the complex life cycle and induce cross-protection against many strains.…”
Section: Discussionmentioning
confidence: 99%